Chen, Li-Shiun
Baker, Timothy
Brownson, Ross C.
Carney, Robert M.
Jorenby, Douglas
Hartz, Sarah
Smock, Nina
Johnson, Mark
Ziedonis, Douglas
Bierut, Laura J.
Funding for this research was provided by:
National Institute on Drug Abuse (R01 DA038076, K08 DA030398, P50 DA19706, K08 DA032680, R01 DA035825)
National Cancer Institute (P50 CA84724, K05CA139871, P30 CA091842)
National Institute of Diabetes and Digestive and Kidney Diseases (KL2 RR024994, 1P30DK092950)
National Center for Advancing Translational Sciences (UL1 TR000448, KL2 TR000450)
Article History
Received: 16 December 2015
Accepted: 22 November 2016
First Online: 30 November 2016
Compliance with Ethical Standards
:
: Dr. Bierut is listed as inventor on issued U.S. Patent 8,080,371, “Markers for Addiction” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Dr. Carney or a member of his family owns stock in Pfizer, Inc. All other authors declare no potential conflict of interest.